The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial.
Leopoldo Martín Baiza-Durán, Jaime Alvarez-Delgado, Angélica Yussett Contreras-Rubio, Javier Medrano-Palafox, Anel De Luca-Brown, Homero Casab-Rueda, Marco Antonio Cortés-Gastélum, Miguel Jorge Garcidueñas-Mejía, Pedro Gómez-Bastar, Félix Gil-Carrasco, Curt Hartleben-Matkin, Jesús Jiménez-Román, Miguel Luis Moreno-Marín, José Antonio Paczka-Zapata, Gustavo Velasco-Gallegos, Mario Vergara-Sinta
{"title":"The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial.","authors":"Leopoldo Martín Baiza-Durán, Jaime Alvarez-Delgado, Angélica Yussett Contreras-Rubio, Javier Medrano-Palafox, Anel De Luca-Brown, Homero Casab-Rueda, Marco Antonio Cortés-Gastélum, Miguel Jorge Garcidueñas-Mejía, Pedro Gómez-Bastar, Félix Gil-Carrasco, Curt Hartleben-Matkin, Jesús Jiménez-Román, Miguel Luis Moreno-Marín, José Antonio Paczka-Zapata, Gustavo Velasco-Gallegos, Mario Vergara-Sinta","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>We compared the efficacy and safety of a new fixed combination of timolol 0.5%/odorzolamide 20%/brimonidine 0.2% in ophthalmic solution versus a fixed combination of timolol 0.5%/dorzolamide 2% in patients with open-angle glaucoma or ocular hypertension. The fixed triple combination was significantly more efficient in mean intraocular pressure reduction from baseline throughout the six-month follow-up.</p>","PeriodicalId":8070,"journal":{"name":"Annals of ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2009-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of ophthalmology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
We compared the efficacy and safety of a new fixed combination of timolol 0.5%/odorzolamide 20%/brimonidine 0.2% in ophthalmic solution versus a fixed combination of timolol 0.5%/dorzolamide 2% in patients with open-angle glaucoma or ocular hypertension. The fixed triple combination was significantly more efficient in mean intraocular pressure reduction from baseline throughout the six-month follow-up.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
